China approves AstraZeneca, Sanofi shot to prevent RSV infection
时间:2024-06-26 19:18:59 阅读(143)
China approved a shot co-developed by AstraZeneca Plc and Sanofi to ward off respiratory syncytial virus in a broad swath of infants, a first in the nation to thwart the highly contagious and potentially fatal infection.
The National Medical Products Administration cleared the long-acting monoclonal antibody Beyfortus to prevent RSV infections in newborns, Astra said in a statement on Tuesday. While RSV has been circulating in China for months, the shot isn’t expected to be available until the upcoming 2024-2025 season, the company said.
RSV causes inflammation of the airways that can lead to difficulty breathing and death in rare cases. Beyfortus is among the first medicines available for widespread use to protect infants from the illness, which affects most children by the age of two.
China has confronted an outsized outbreak of respiratory diseases since the second half of 2023, with children particularly hard hit by a barrage of common pathogens including RSV, flu and mycoplasma pneumoniae. The surge in disease has stretched some pediatric medical centers across the country beyond capacity.
上一篇:Japan earthquake update- Rescue operations continue after four days
下一篇:Zell Education introduces global career championship; a financial education scholarship
猜你喜欢
- Sensex, Nifty end in red for 7th straight day amid volatility on F&O expiry; all eyes on RBI MPC meet decision
- SEC reward puts spotlight on India’s whistle-blower policy
- Strategies for reducing educational disparities and ensuring equal opportunities for all students
- Sebi to digitise processing of investor service requests, complaints by RTAs
- Sensex ends in red after volatile trading session, Nifty needs to breach 16400 for any up-move
- Studying in Canada to get costlier from January 1, 2024
- Strengthening Disclosure Requirements- Enhancing Transparency in Financial Markets
- Sensex, Nifty open in red on Friday; IRCTC shares fall 2%, Landmark Cars in focus today
- Tata Starbucks reports loss of Rs 24